As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
Subscribe To Our Newsletter & Stay Updated
